A Randomized, Blinded, Placebo-Controlled Six Month Treatment Trial of Aliskiren to Improve Exercise Tolerance in Older Patients With Heart Failure and Normal Ejection Fraction.
Phase of Trial: Phase IV
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Aliskiren (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- 09 Jan 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 09 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2011 Planned End Date changed from 1 Jun 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.